Molnár I, Bohaty I, Somogyiné-Vári É
Immunoendocrinology and Osteoporosis Centre, EndoMed, Bem tér 18/C, 4026, Debrecen, Hungary,
Osteoporos Int. 2014 Feb;25(2):783-6. doi: 10.1007/s00198-013-2548-6. Epub 2013 Dec 13.
The role of proinflammatory IL-17 cytokine was studied in postmenopausal bone loss between 31 osteopenic and 41 osteoporotic women. The effect of serum IL-17A, soluble receptor activator of NF-κB (sRANK) ligand, and osteoprotegerin (OPG) levels on lumbar bone mineral densities was measured. The results demonstrated an increased IL-17A-mediated sRANK ligand elevation in postmenopausal osteoporotic bone loss.
IL-17 proinflammatory cytokine is a new inducer of bone loss. Postmenopausal osteoporosis represents a cross talk between estrogen deprivation and increased immune reactivity. The role of IL-17 was studied in the bone loss of postmenopausal osteoporosis.
Serum IL-17A, sRANK ligand, and OPG levels were investigated on bone mineral densities (BMDs) in the total lumbar (L1-L4) region in 18 pre- and 72 postmenopausal women. IL-17A, sRANK ligand, OPG levels, and BMDs were measured with enzyme-linked immunosorbent assay (ELISA) and dual-energy X-ray absorptiometry (DXA).
Increased serum IL-17A, sRANK ligand, and OPG levels were demonstrated in postmenopausal osteoporotic women compared to osteopenic women (3.65 ± 0.61 vs 3.31 ± 0.43 ng/ml for IL-17A, P < 0.007; 2.88 ± 0.84 vs 2.49 ± 0.61 ng/ml for sRANK ligand, P < 0.027; and 1.43 ± 0.07 vs 1.39 ± 0.07 ng/ml for OPG, P < 0.038). In postmenopausal women, IL-17A levels correlated inversely with total lumbar BMDs (P < 0.008, r = -0.279) and positively with sRANK ligand levels (P < 0.0001, r = 0.387) or the ratio of sRANK ligand and OPG (P < 0.013, r = 0.261), but did not with OPG levels alone.
Increased IL-17A levels are involved in postmenopausal osteoporosis, playing a role in the bone-resorpting processes.
在31名骨质减少和41名骨质疏松的绝经后女性中，研究了促炎细胞因子IL-17在绝经后骨质流失中的作用。测量了血清IL-17A、可溶性核因子κB受体激活剂（sRANK）配体和骨保护素（OPG）水平对腰椎骨密度的影响。结果表明，在绝经后骨质疏松性骨质流失中，IL-17A介导的sRANK配体升高。
IL-17促炎细胞因子是骨质流失的一种新诱导剂。绝经后骨质疏松代表雌激素缺乏和免疫反应性增加之间的相互作用。研究了IL-17在绝经后骨质疏松骨质流失中的作用。
在18名绝经前和72名绝经后女性的整个腰椎（L1-L4）区域，研究血清IL-17A、sRANK配体和OPG水平对骨密度（BMD）的影响。采用酶联免疫吸附测定（ELISA）和双能X线吸收法（DXA）测量IL-17A、sRANK配体、OPG水平和BMD。
与骨质减少的女性相比，绝经后骨质疏松女性的血清IL-17A、sRANK配体和OPG水平升高（IL-17A为3.65±0.61 vs 3.31±0.43 ng/ml，P<0.007；sRANK配体为2.88±0.84 vs 2.49±0.61 ng/ml，P<0.027；OPG为1.43±0.07 vs 1.39±0.07 ng/ml，P<0.038）。在绝经后女性中，IL-17A水平与总腰椎BMD呈负相关（P<0.008，r=-0.279），与sRANK配体水平呈正相关（P<0.0001，r=0.387）或sRANK配体与OPG的比值呈正相关（P<0.013，r=0.261），但与单独的OPG水平无关。
IL-17A水平升高与绝经后骨质疏松有关，在骨吸收过程中起作用。
